GLSI vs GRCE

Greenwich LifeSciences, Inc. vs Grace Therapeutics, Inc. — Valuation Comparison 2026

GLSI

Biotechnology
Greenwich LifeSciences, Inc.
Quality
4.0
out of 10
Value Trap
Price
$28.99
Last close
Models
6/13
Active
VS

GRCE

Biotechnology
Grace Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
52
WARN
Price
$2.43
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType GLSI Fair ValueGLSI Upside GRCE Fair ValueGRCE Upside
Bayesian DCF Intrinsic $7.90 -72.7% $1.31 -46.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $4.05 +66.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $27.15 -6.3% $2.52 +3.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GLSI vs GRCE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GLSI vs GRCE — Which Stock Is More Undervalued?

GRCE scores higher with a 4.6/10 quality rating vs GLSI's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Greenwich LifeSciences, Inc. (GLSI) and Grace Therapeutics, Inc. (GRCE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GLSI currently trades at $28.99 with a QOC of 4.0/10, while GRCE trades at $2.43 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).